Skip to Content

Chembio's stock more than doubles off 11-year low after large order for COVID-19 antigen tests

Shares of Chembio Diagnostics Inc. (CEMI) rocketed 102% on heavy volume in premarket trading Wednesday, infectious diseases diagnostic company announced a $28.3 million purchase order its SARS-CoV-2 antigen tests from Brazil-based Bio-Manguinhos. Trading volume spiked to 22.3 million shares, compared with the full-day average of about 525,100 shares. The stock was the biggest gainer and most actively traded ahead of the open. Chembio's SARS-CoV-2 antigen test is designed to detect an active COVID-19 infection in 20 minutes using a nasal swab. The order from Bio-Manguinhos, a subsidiary of the Oswaldo Cruz Foundation, is for delivery during 2021. To put the $28.3 million order in perspective, Chembio recorded total revenue of $32.47 million in 2020. Benchmark analyst Bruce Jackson said the order win is "important" for the company, as it tries to improve its cash position and manage its working capital. The stock, which closed Tuesday at an 11-year low, has tumbled 56.6% year to date while the Nasdaq Composite has gained 12.5% and the S&P 500 has advanced 15.1%.

-Tomi Kilgore; 415-439-6400;


(END) Dow Jones Newswires

07-21-21 0850ET

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.